| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6455499 | SPECIALITY EUROPEAN | Methods for treating disorders associated with LHRH activity |
Jun, 2015
(8 years ago) | |
| US6423686 | SPECIALITY EUROPEAN | LHRH antagonist peptides |
Jun, 2015
(8 years ago) | |
| US5843901 | SPECIALITY EUROPEAN | LHRH antagonist peptides |
Dec, 2015
(8 years ago) | |
| US5968895 | SPECIALITY EUROPEAN | Pharmaceutical formulations for sustained drug delivery |
Dec, 2016
(7 years ago) | |
| US6180608 | SPECIALITY EUROPEAN | Pharmaceutical formulations for sustained drug delivery |
Dec, 2016
(7 years ago) | |
| US6699833 | SPECIALITY EUROPEAN | Pharmaceutical formulations for sustained drug delivery |
Dec, 2016
(7 years ago) | |
Plenaxis is owned by Speciality European.
Plenaxis contains Abarelix.
Plenaxis has a total of 6 drug patents out of which 6 drug patents have expired.
Expired drug patents of Plenaxis are:
- US6455499
- US6423686
- US5843901
- US5968895
- US6180608
- US6699833
Plenaxis was authorised for market use on 25 November, 2003.
Plenaxis is available in injectable;intramuscular dosage forms.
Plenaxis can be used as use in the treatment of men with advanced symptomatic prostate cancer.
The generics of Plenaxis are possible to be released after 11 December, 2016.
Drugs and Companies using ABARELIX ingredient
Market Authorisation Date: 25 November, 2003
Treatment: Use in the treatment of men with advanced symptomatic prostate cancer
Dosage: INJECTABLE;INTRAMUSCULAR
PLENAXIS family patents
